Nurix Therapeutics (NRIX) closed at $26.80 on October 30, 2026, down 1.2% from the previous close, on volume of 1,992,934 shares (30-day average 2,250,272).
Data as of October 30, 2026.
30-Oct-2026
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Mon, 12-Oct 4:05 PM ET)
Globe Newswire (Wed, 7-Oct 1:00 AM ET)
Globe Newswire (Mon, 5-Oct 7:00 AM ET)
Globe Newswire (Tue, 29-Sep 7:00 AM ET)
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Globe Newswire (Thu, 20-Aug 7:00 AM ET)
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
Globe Newswire (Tue, 4-Aug 1:00 AM ET)
Market Chameleon (Thu, 11-Jun 7:08 AM ET)
Market Chameleon (Mon, 8-Jun 5:55 AM ET)
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Nurix Therapeutics trades on the NASDAQ stock market under the symbol NRIX.
As of October 30, 2026, NRIX stock price declined to $26.80 with 1,992,934 million shares trading.
NRIX has a beta of 0.92, meaning it tends to be less sensitive to market movements. NRIX has a correlation of 0.03 to the broad based SPY ETF.
NRIX has a market cap of $2.93 billion. This is considered a Mid Cap stock.
Last quarter Nurix Therapeutics reported $673 million in Revenue and $4.73 earnings per share. This beat revenue expectation by $262 million and exceeded earnings estimates by $.75.
In the last 3 years, NRIX traded as high as $29.56 and as low as $4.96.
The top ETF exchange traded funds that NRIX belongs to (by Net Assets): VTI, IWM, ARKG, XBI, VXF.
NRIX has outperformed the market in the last year with a price return of +109.7% while the SPY ETF gained +12.3%. NRIX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +13.7% and +9.7%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
NRIX support price is $26.11 and resistance is $28.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRIX shares will trade within this expected range on the day.
